Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 1 | Harm Reduction Journal

Fig. 1

From: Opioid consumption frequency and its associations with potential life problems during opioid agonist treatment in individuals with prescription-type opioid use disorder: exploratory results from the OPTIMA Study

Fig. 1

CONSORT flow diagram showing how analyzed participants in the present study were selected and retained. a Thirteen participants were screened twice but are counted only once in the flowchart. b Other reasons for exclusions were unspecified (n = 14), incomplete screening (n = 4), failure to complete baseline visit within a 28-day time window (n = 3), and incarceration (n = 1). c One participant attempted suicide and withdrew consent six days later. ASI, Addiction Severity Index Self-Report; TLFB, Timeline Follow-Back; BUP/NX, buprenorphine/naloxone; COVID-19, coronavirus disease 2019; n, number of participants; OAT, opioid agonist treatment; POUD, prescription-type opioid use disorder; SAE, serious adverse events

Back to article page

Harm Reduction Journal

ISSN: 1477-7517